•
Jun 30, 2023

Danaher Q2 2023 Earnings Report

Danaher's second quarter results met expectations, with better-than-expected performance in Life Science and Diagnostics businesses offsetting softer demand in bioprocessing.

Key Takeaways

Danaher reported Q2 2023 results with revenues decreasing 7.5% year-over-year to $7.2 billion. Net earnings were $1.1 billion, or $1.49 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $2.05. The company anticipates non-GAAP base business core revenue will be down low-single digits year-over-year for Q3 2023 and up low-single digits year-over-year for full year 2023.

Revenues decreased 7.5% year-over-year to $7.2 billion.

Net earnings were $1.1 billion, or $1.49 per diluted common share.

Non-GAAP adjusted diluted net earnings per common share were $2.05.

Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.

Total Revenue
$7.16B
Previous year: $7.75B
-7.7%
EPS
$2.05
Previous year: $2.76
-25.7%
Core Sales Growth
-7%
Previous year: 9.5%
-173.7%
Gross Profit
$4.04B
Previous year: $4.72B
-14.4%
Cash and Equivalents
$8.58B
Previous year: $3.98B
+115.2%
Free Cash Flow
$1.6B
Previous year: $1.71B
-6.5%
Total Assets
$84.9B
Previous year: $81.8B
+3.8%

Danaher

Danaher

Forward Guidance

For the third quarter 2023, the Company anticipates that non-GAAP base business core revenue will be down low-single digits year-over-year. For full year 2023, the Company anticipates that non-GAAP base business core revenue growth will be up low-single digits year-over-year.